MFT-Male match

MFT-Female match

 

Transsexuals (n=53)

DETECT (n=149)

 

Transsexuals (n=56)

DETECT (n=160)

 

 

mean

SD

mean

SD

p

mean

SD

mean

SD

p

Age

49.1

10.9

46.5

9.8

0.114

48.5

11.0

45.2

10.7

0.054

Age at diagnosis

38.6

11.7

-

-

-

38.6

11.7

-

-

-

Length of HT

6.5

7.9

-

-

-

6.5

7.9

-

-

-

Diseases

n

%

n

%

p

n

%

n

%

p

Cardiovascular

8

15.1

68

45.6

0.000

8

14.3

56

35.0

0.005

Respiratory

10

18.9

11

7.4

0.023

10

17.9

11

6.9

0.021

Neurological

10

18.9

21

14.1

0.410

12

21.4

13

8.1

0.010

Endocrine

4

7.6

81

54.4

0.000

4

7.1

77

48.1

0.000

Gastroenterological

10

18.9

33

22.2

0.618

10

17.9

29

18.1

0.964

Urinary

5

9.4

14

9.4

0.994

6

10.7

21

13.1

0.640

Tumoural

1

1.9

5

3.4

0.595

1

1.8

14

8.8

0.113

Immune-mediated

6

11.3

6

4.0

0.065

6

10.7

6

3.8

0.061

BMI (mean/SD)

25.2

4.7

27.8

4.4

0.000

25.2

4.7

27.0

6.1

0.027

There is no indication of an increased risk associated with hormone treatment in transsexual patients. The values presented are means ± standard deviation (SD) or total number (n) and percentage (%). Up to 3 controls were matched for each patient. Differences in the number of transsexual patients within the same row of the table are due to differences in the availability of age-matched control subjects. MFT: male-to-female transsexuals; p: p-value.
Table 2: Lifetime comorbidities in male-to-female transsexuals in comparison to age- and gender-matched comparison groups from the DETECT-Cohort.